 Large Insiders Are Buying Biotech — What Does It Mean? Yesterday's OpenInsider data shows unusual activity: insiders invested $100+ million in stocks in a single day. And the lion's share went into biotech and pharma. Top 3 deals: 1. Genedx Holdings (WGS) — $46.8 million. A director bought at $38.84, increasing their stake by 34%. This is diagnostic genomics. 2. Odyssey Therapeutics (ODTX) — $30 million total from two insiders. One insider's stake grew by 50%. Oncology and immunology. 3. Pulse Biosciences (PLSE) — $13 million. Robert Duggan is increasing his position. Also notable: Mobia Medical (MOBI) — two insiders, one of whom opened a new position. Atara Biotherapeutics (ATRA) — a $4.7 million purchase. Hemab Therapeutics (COAG) — $1.27 million. Insiders usually don't throw money around. When directors and large funds simultaneously enter a sector, it's a signal. Non-biotech: Starlink AI Acquisition (OTAI) — a $2.2 million purchase, AI theme is alive. Legalzoom (LZ) — CEO bought $769k. Conclusion: The biotech sector is attracting insider capital. If they believe in a recovery, it might be worth taking a closer look. https://asibiont.com/